Northpond Ventures

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Founded in 2019 and headquartered in Waltham, Massachusetts, Eleanor offers comprehensive, whole-person care for mental health and substance misuse. The company operates a network of outpatient clinics and also provides virtual care as well as support in patients' homes and communities. Its services include medication-assisted treatment, evidence-based outpatient care, behavioral health services, and personalized recovery plans, all aimed at facilitating a faster recovery process for individuals suffering from substance abuse disorder.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that integrate devices, software, and services to support patients in monitoring their health and managing diseases. By bridging the gap between diagnosis and treatment, Vital Bio aims to empower patients and healthcare providers alike, promoting proactive care and reducing disparities in health outcomes. The company's innovative approach seeks to enhance the overall healthcare experience, ensuring that individuals have greater control over their health management.

SpeeDx is a company that specializes in molecular diagnostic solutions, offering advanced testing systems that provide comprehensive information for enhanced patient management. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx develops market-leading multiplex detection and priming strategies. Its product portfolio includes diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By focusing on multiplex systems, SpeeDx enables healthcare providers to efficiently test for various infectious diseases and assess antibiotic resistance, thereby improving clinical decision-making and patient outcomes.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Founded in 2019 and headquartered in Waltham, Massachusetts, Eleanor offers comprehensive, whole-person care for mental health and substance misuse. The company operates a network of outpatient clinics and also provides virtual care as well as support in patients' homes and communities. Its services include medication-assisted treatment, evidence-based outpatient care, behavioral health services, and personalized recovery plans, all aimed at facilitating a faster recovery process for individuals suffering from substance abuse disorder.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Story Health Corporation is a healthcare technology company founded in 2020 and based in Saratoga, California. The company develops intelligent embedded virtualized clinical care software tools designed to assist healthcare specialists, including neurologists and primary care physicians, in understanding medical situations and making informed clinical decisions. Story Health's platform utilizes data from high-frequency sources to enhance therapy management through virtual protocols and adaptive machine learning. By focusing on patient-centered design, Story Health aims to bridge the gap between clinical evidence and real-world patient experiences, enabling clinicians to effectively address the physiological effects of disease and therapy.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

Hawthorne Effect is a company focused on transforming the landscape of clinical trials by making them more accessible and convenient for participants. It operates a clinical trial data platform that integrates licensed healthcare professionals with advanced technology to facilitate decentralized clinical trials. This innovative approach enhances efficiency and accuracy compared to traditional models, allowing for real-time consultations and follow-ups between patients and doctors. The company's proactive Visit Management System fosters strong relationships between sponsors and investigators, ensuring protocol compliance and minimizing data loss. By deploying specially trained healthcare providers, known as HEROs, Hawthorne Effect guarantees that patients remain engaged throughout the trial process, effectively addressing the issue of patients being “lost to follow-up.” Through these initiatives, Hawthorne Effect aims to democratize access to clinical research, ensuring that trials can reach a broader audience.

Torus Biosystems is a biotechnology company founded in 2019 and based in Cambridge, Massachusetts. It specializes in the development of a diagnostic device that facilitates DNA testing for scientific and medical research applications. The company's apparatus is designed for use across various sectors, including consumer products, food safety for humans and animals, personal care, and agriculture. By providing accessible DNA testing solutions, Torus Biosystems aims to enhance the understanding of biochemical agents in both medical and non-medical contexts.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

Outcomes4me Inc. is a healthcare technology company based in Cambridge, Massachusetts, founded in 2017. It has developed an AI-driven patient empowerment platform specifically designed for cancer patients, enabling them to take a proactive approach in managing their care. The platform provides personalized, evidence-based treatment options and real-time clinical information, facilitating informed decision-making and improving patient outcomes. By connecting patients with healthcare providers and offering resources related to breast cancer treatment and clinical trials, Outcomes4me aims to democratize healthcare and promote health equity. The company is led by a team of experienced professionals from healthcare, oncology, pharmaceuticals, and technology sectors, dedicated to generating insights that enhance care and accelerate research and access to innovative treatments.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development and manufacturing of reagents for marker multiplexing detection and analysis. Founded in 2015, the company focuses on tissue imaging, diagnostics, and multiplexing to enhance research in the life sciences and biomedical fields. Ultivue's innovative technologies, including DNA-PAINT and DNA-Exchange, facilitate the collection of high-resolution microscopic images that contribute to a deeper understanding of biological processes and diseases. The company’s multiplex biomarker assays are designed for tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine. Ultivue's products are intended for fluorescent microscopy-based research and hold potential for clinical diagnostic applications.

Current Health Limited is a healthcare technology company based in Edinburgh, United Kingdom, that specializes in wearable devices for monitoring patient vitals. Founded in 2014 and originally known as Snap40 Limited, the company rebranded in December 2018. Current Health's devices are designed to measure critical health indicators such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, enabling early identification of potential health issues. Their patient monitoring platform facilitates the management of patients at home by collecting and analyzing data to detect and predict health deterioration. This allows patients to share daily activities, report symptoms, and complete structured questionnaires, ultimately helping healthcare providers reduce risks and costs associated with patient care.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

SpeeDx is a company that specializes in molecular diagnostic solutions, offering advanced testing systems that provide comprehensive information for enhanced patient management. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx develops market-leading multiplex detection and priming strategies. Its product portfolio includes diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By focusing on multiplex systems, SpeeDx enables healthcare providers to efficiently test for various infectious diseases and assess antibiotic resistance, thereby improving clinical decision-making and patient outcomes.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

SpeeDx is a company that specializes in molecular diagnostic solutions, offering advanced testing systems that provide comprehensive information for enhanced patient management. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx develops market-leading multiplex detection and priming strategies. Its product portfolio includes diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By focusing on multiplex systems, SpeeDx enables healthcare providers to efficiently test for various infectious diseases and assess antibiotic resistance, thereby improving clinical decision-making and patient outcomes.

SpeeDx is a company that specializes in molecular diagnostic solutions, offering advanced testing systems that provide comprehensive information for enhanced patient management. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx develops market-leading multiplex detection and priming strategies. Its product portfolio includes diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By focusing on multiplex systems, SpeeDx enables healthcare providers to efficiently test for various infectious diseases and assess antibiotic resistance, thereby improving clinical decision-making and patient outcomes.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development and manufacturing of reagents for marker multiplexing detection and analysis. Founded in 2015, the company focuses on tissue imaging, diagnostics, and multiplexing to enhance research in the life sciences and biomedical fields. Ultivue's innovative technologies, including DNA-PAINT and DNA-Exchange, facilitate the collection of high-resolution microscopic images that contribute to a deeper understanding of biological processes and diseases. The company’s multiplex biomarker assays are designed for tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine. Ultivue's products are intended for fluorescent microscopy-based research and hold potential for clinical diagnostic applications.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Outcomes4me Inc. is a healthcare technology company based in Cambridge, Massachusetts, founded in 2017. It has developed an AI-driven patient empowerment platform specifically designed for cancer patients, enabling them to take a proactive approach in managing their care. The platform provides personalized, evidence-based treatment options and real-time clinical information, facilitating informed decision-making and improving patient outcomes. By connecting patients with healthcare providers and offering resources related to breast cancer treatment and clinical trials, Outcomes4me aims to democratize healthcare and promote health equity. The company is led by a team of experienced professionals from healthcare, oncology, pharmaceuticals, and technology sectors, dedicated to generating insights that enhance care and accelerate research and access to innovative treatments.